Trial Profile

A Phase 1b Master Protocol of Agents Targeting the Mitogen-Activated Protein Kinase Pathway in Patients With Advanced Non-Small-Cell Lung Cancer

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 27 Jul 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ERAS 007 (Primary) ; ERAS-601 (Primary) ; Osimertinib (Primary) ; Sotorasib (Primary)
Indications Non-small cell lung cancer
Focus Adverse reactions
Acronyms HERKULES-2
Sponsors Erasca

Most Recent Events

24 Jul 2023 Status changed from active, no longer recruiting to completed.
15 May 2023 According to an Erasca media release, Initial Phase 1b combination data expected in the second quarter of 2023
23 Mar 2023 According to an Erasca media release, initial combination data expected in first half of 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com